Pancreatic Cancer Drug Daraxonrasib Nearly Doubles Survival
Original: Treating pancreatic tumours may have revealed cancer's master switch
Why This Matters
Major breakthrough in pancreatic cancer treatment could launch new drug class
Daraxonrasib, a new pancreatic cancer drug, nearly doubled median survival times from 6.7 months to 13.2 months in clinical trials. The results presented at a Chicago conference received standing ovation from oncologists.
At a recent oncology conference in Chicago, researchers presented breakthrough results for daraxonrasib, a new drug treating pancreatic cancer. The treatment nearly doubled median survival times from 6.7 months to 13.2 months, representing a significant advancement against one of medicine's most challenging cancers. The presentation prompted thousands of scientists to give a spontaneous standing ovation with cheering, an unusual emotional response in the typically reserved scientific community. The drug's success suggests it could be the first of an entirely new class of cancer treatments, potentially representing what researchers describe as cancer's 'master switch.'